{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T08:52:14Z","timestamp":1780649534728,"version":"3.54.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-022-03227-0","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T20:23:06Z","timestamp":1668198186000},"page":"527-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating home injection compared with healthcare-setting injection of somatostatin analogs: a systematic literature review"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7285-7941","authenticated-orcid":false,"given":"Cesar L.","family":"Boguszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-9432","authenticated-orcid":false,"given":"M\u00e1rta","family":"Korbonits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0354-1158","authenticated-orcid":false,"given":"Audrey","family":"Artignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almudena Mart\u00edn","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6248-8986","authenticated-orcid":false,"given":"Aude","family":"Houchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6114-5786","authenticated-orcid":false,"suffix":"Jr","given":"Antonio","family":"Ribeiro-Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1463-5165","authenticated-orcid":false,"given":"Wouter W.","family":"de Herder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"3227_CR1","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"M. Fleseriu, M. Molitch, A. Dreval, N.R. Biermasz, M.B. Gordon, R.D. Crosby, W.H. Ludlam, A. Haviv, Y. Gilgun-Sherki, S.D. Mathias, Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front. Endocrinol. 12, 627711 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.627711","journal-title":"Front. Endocrinol."},{"issue":"2","key":"3227_CR2","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1210\/endrev\/bnz004","volume":"41","author":"J Hofland","year":"2020","unstructured":"J. Hofland, G. Kaltsas, W.W. de Herder, Advances in the diagnosis and management of well-differentiated neuroendocrine neoplasms. Endocr. Rev. 41(2), 371\u2013403 (2020)","journal-title":"Endocr. Rev."},{"key":"3227_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/ijgm.S38594","volume":"6","author":"DT Adelman","year":"2013","unstructured":"D.T. Adelman, K.J. Liebert, L.B. Nachtigall, M. Lamerson, B. Bakker, Acromegaly: The disease, its impact on patients, and managing the burden of long-term treatment. Int J. Gen. Med. 6, 31\u201338 (2013). https:\/\/doi.org\/10.2147\/ijgm.S38594","journal-title":"Int J. Gen. Med."},{"issue":"10","key":"3227_CR4","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.1503\/cmaj.160771","volume":"189","author":"MJ Raphael","year":"2017","unstructured":"M.J. Raphael, D.L. Chan, C. Law, S. Singh, Principles of diagnosis and management of neuroendocrine tumours. CMAJ 189(10), e398\u2013e404 (2017). https:\/\/doi.org\/10.1503\/cmaj.160771","journal-title":"CMAJ"},{"key":"3227_CR5","volume-title":"Acromegaly","author":"OO Adigun","year":"2022","unstructured":"O.O. Adigun, M. Nguyen, T.J. Fox, C. Anastasopoulou. Acromegaly. (StatPearls Publishing, Florida), 2022)"},{"key":"3227_CR6","unstructured":"National Health Service (NHS): Acromegaly. https:\/\/www.nhs.uk\/conditions\/acromegaly\/. Accessed 16 August 2022"},{"issue":"5","key":"3227_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/mpa.0000000000000818","volume":"46","author":"EM Wolin","year":"2017","unstructured":"E.M. Wolin, J. Leyden, G. Goldstein, T. Kolarova, R. Hollander, R.R.P. Warner, Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: results from a large patient survey in the United States. Pancreas 46(5), 639\u2013647 (2017). https:\/\/doi.org\/10.1097\/mpa.0000000000000818","journal-title":"Pancreas"},{"issue":"1","key":"3227_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5057-3","volume":"18","author":"R Basuroy","year":"2018","unstructured":"R. Basuroy, C. Bouvier, J.K. Ramage, M. Sissons, R. Srirajaskanthan, Delays and routes to diagnosis of neuroendocrine tumours. BMC Cancer 18(1), 1122 (2018). https:\/\/doi.org\/10.1186\/s12885-018-5057-3","journal-title":"BMC Cancer"},{"key":"3227_CR9","unstructured":"Sandostatin LAR: The goal of neuroendocrine tumor therapy. https:\/\/www.sandostatin.com\/en\/neuroendocrine-tumors\/treating-net\/treatment-goal\/. Accessed 16 August 2022"},{"issue":"5","key":"3227_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2020","unstructured":"M. Gomes-Porras, J. C\u00e1rdenas-Salas, C. \u00c1lvarez-Escol\u00e1, Somatostatin analogs in clinical practice: a review. Int J. Mol. Sci. 21(5), 1\u201327 (2020)","journal-title":"Int J. Mol. Sci."},{"key":"3227_CR11","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.2147\/dddt.S76732","volume":"10","author":"RM Paragliola","year":"2016","unstructured":"R.M. Paragliola, A. Prete, G. Papi, F. Torino, A. Corsello, A. Pontecorvi, S.M. Corsello, Clinical utility of lanreotide Autogel(\u00ae) in gastroenteropancreatic neuroendocrine tumors. Drug Des. Devel Ther. 10, 3459\u20133470 (2016). https:\/\/doi.org\/10.2147\/dddt.S76732","journal-title":"Drug Des. Devel Ther."},{"key":"3227_CR12","unstructured":"Food and Drug Administration (FDA): Somatuline depot prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/022074s024lbl.pdf. Accessed 16 August 2022"},{"key":"3227_CR13","unstructured":"Electronic Medicines Compendium (EMC): Somatuline autogel 60mg, somatuline autogel 90mg, somatuline autogel 120mg. https:\/\/www.medicines.org.uk\/emc\/medicine\/25104#gref. Accessed 16 August 2022"},{"key":"3227_CR14","unstructured":"European Medicines Agency (EMA): Sandostatin LAR summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/sandostatin-lar-article-30-referral-annex-iii_en.pdf. Accessed 16 August 2022"},{"key":"3227_CR15","unstructured":"Food and Drug Administration (FDA): Sandostatin LAR prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/021008s041lbl.pdf. Accessed 16 August 2022"},{"issue":"4","key":"3227_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1124\/pr.117.015388","volume":"70","author":"T G\u00fcnther","year":"2018","unstructured":"T. G\u00fcnther, G. Tulipano, P. Dournaud, C. Bousquet, Z. Csaba, H.-J. Kreienkamp, A. Lupp, M. Korbonits, J.P. Casta\u00f1o, H.-J. Wester, International union of basic and clinical pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharm. Rev. 70(4), 763\u2013835 (2018)","journal-title":"Pharm. Rev."},{"key":"3227_CR17","unstructured":"Ipsen Biopharmaceuticals: Somatuline autogel product monograph. https:\/\/www.ipsen.com\/websites\/Ipsen_Online\/wp-content\/uploads\/sites\/61\/2021\/04\/23163136\/PM-Somatuline-Autogel-EN-25Mar2021.pdf (2021). Accessed 16 August 2022"},{"key":"3227_CR18","unstructured":"Novartis Pharmaceuticals Canada Inc.: Sandostatin LAR Product Monograph. https:\/\/www.ask.novartispharma.ca\/download.htm?res=sandostatin_scrip_e.pdf&resTitleId=789 (2021). Accessed 16 August 2022"},{"key":"3227_CR19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/ceor.S140866","volume":"9","author":"JD Ortendahl","year":"2017","unstructured":"J.D. Ortendahl, S.J. Pulgar, B. Mirakhur, D. Cox, T.G. Bentley, A.T. Phan, Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. Clinicoecon Outcomes Res. 9, 495\u2013503 (2017). https:\/\/doi.org\/10.2147\/ceor.S140866","journal-title":"Clinicoecon Outcomes Res."},{"key":"3227_CR20","first-page":"176","volume":"34","author":"J Hernando","year":"2022","unstructured":"J. Hernando, T. Kolarova, C. Verslype, G. Kaltsas, A. Houchard, D. Gueguen, W. de Herder, HomeLAN: An international online survey to assess satisfaction with injection experience of patients with neuroendocrine tumors (NETs) enrolled in lanreotide autogel (LAN) Patient Support Programmes (PSPs). J. Neuroendocrinol. 34, 176 (2022)","journal-title":"J. Neuroendocrinol."},{"issue":"1","key":"3227_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/msc.110","volume":"6","author":"F Chilton","year":"2008","unstructured":"F. Chilton, R.A. Collett, Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet. Care 6(1), 1\u201314 (2008). https:\/\/doi.org\/10.1002\/msc.110","journal-title":"Musculoskelet. Care"},{"issue":"2","key":"3227_CR22","first-page":"302","volume":"26","author":"AB Arthur","year":"1999","unstructured":"A.B. Arthur, A.V. Klinkhoff, A. Teufel, Safety of self-injection of gold and methotrexate. J. Rheumatol. 26(2), 302\u2013305 (1999)","journal-title":"J. Rheumatol."},{"issue":"2","key":"3227_CR23","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s40744-017-0080-4","volume":"4","author":"M Schiff","year":"2017","unstructured":"M. Schiff, S. Saunderson, I. Mountian, P. Hartley, Chronic disease and self-injection: ethnographic investigations into the patient experience during treatment. Rheumatol. Ther. 4(2), 445\u2013463 (2017). https:\/\/doi.org\/10.1007\/s40744-017-0080-4","journal-title":"Rheumatol. Ther."},{"issue":"2","key":"3227_CR24","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s12325-020-01600-x","volume":"38","author":"D Cella","year":"2021","unstructured":"D. Cella, J. Evans, M. Feuilly, S. Neggers, D. Van Genechten, J. Herman, M.S. Khan, Patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review. Adv. Ther. 38(2), 969\u2013993 (2021). https:\/\/doi.org\/10.1007\/s12325-020-01600-x","journal-title":"Adv. Ther."},{"key":"3227_CR25","unstructured":"S. Khawaja, M. Marks, M. Gurnell, ACROCOVID II: An international survey on acromegaly management more than 1 year into the COVID-19 pandemic era. Presented at NORD Rare Summit (2021), Virtual"},{"issue":"6","key":"3227_CR26","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1164\/rccm.200906-0907OC","volume":"181","author":"SR Wilson","year":"2010","unstructured":"S.R. Wilson, P. Strub, A.S. Buist, S.B. Knowles, P.W. Lavori, J. Lapidus, W.M. Vollmer, Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Am. J. Respir. Crit. Care Med. 181(6), 566\u2013577 (2010). https:\/\/doi.org\/10.1164\/rccm.200906-0907OC","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3227_CR27","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"M.J. Page, J.E. McKenzie, P.M. Bossuyt, I. Boutron, T.C. Hoffmann, C.D. Mulrow, L. Shamseer, J.M. Tetzlaff, E.A. Akl, S.E. Brennan, R. Chou, J. Glanville, J.M. Grimshaw, A. Hr\u00f3bjartsson, M.M. Lalu, T. Li, E.W. Loder, E. Mayo-Wilson, S. McDonald, L.A. McGuinness, L.A. Stewart, J. Thomas, A.C. Tricco, V.A. Welch, P. Whiting, D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021). https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3227_CR28","unstructured":"National Institute for Health Research (NIHR): PROSPERO. Evaluating patient outcomes and preferences for independent injection of somatostatin analogues: a systematic literature review. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=279886. Accessed 16 August 2022"},{"key":"3227_CR29","first-page":"P411","volume":"81","author":"CL Boguszewski","year":"2022","unstructured":"C.L. Boguszewski, M. Korbonits, A. Artignan, G.A. Martin, A. Houchard, A. Ribeiro-Oliveira, Independent injection vs healthcare-setting administration of somatostatin analogues: A systematic literature review. Endocr. Abstr. 81, P411 (2022)","journal-title":"Endocr. Abstr."},{"key":"3227_CR30","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood-2019-125505","volume":"134","author":"C Zhang","year":"2019","unstructured":"C. Zhang, X. Cao, D. Li, Home treatment of bortezomib: a preliminary exploration of a new treatment mode in China. Blood 134, 2127 (2019)","journal-title":"Blood"},{"key":"3227_CR31","unstructured":"Centre for Reviews and Dissemination (CRD). Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care. (York Publ. Services, York, 2009)."},{"issue":"6","key":"3227_CR32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","volume":"52","author":"SH Downs","year":"1998","unstructured":"S.H. Downs, N. Black, The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J. Epidemiol. Commun. Health 52(6), 377\u2013384 (1998). https:\/\/doi.org\/10.1136\/jech.52.6.377","journal-title":"J. Epidemiol. Commun. Health"},{"issue":"2","key":"3227_CR33","first-page":"60","volume":"27","author":"L Cortez","year":"2021","unstructured":"L. Cortez, An evaluation of the impact of self or partner administration of lanreotide within a pharmacist-led homecare service for patients with neuroendocrine tumours (NET). J. Oncol. Pharm. Pr. 27(2), 60\u201361 (2021)","journal-title":"J. Oncol. Pharm. Pr."},{"issue":"4","key":"3227_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1530\/ec-16-0038","volume":"5","author":"C Follin","year":"2016","unstructured":"C. Follin, S. Karlsson, Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues. Endocr. Connect 5(4), 167\u2013173 (2016). https:\/\/doi.org\/10.1530\/ec-16-0038","journal-title":"Endocr. Connect"},{"key":"3227_CR35","first-page":"192","volume":"110","author":"J Gertner","year":"2020","unstructured":"J. Gertner, A. McSweeney, F.L. O'Mahony, E. Quaglia, A. John, D. Mandair, M. Caplin, C. Toumpanakis, Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients\u2019 Experience. Neuroendocrinol 110, 192 (2020)","journal-title":"Neuroendocrinol"},{"issue":"1","key":"3227_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11102-012-0460-2","volume":"17","author":"R Salvatori","year":"2014","unstructured":"R. Salvatori, W.W. Woodmansee, M. Molitch, M.B. Gordon, K.G. Lomax, Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary 17(1), 13\u201321 (2014). https:\/\/doi.org\/10.1007\/s11102-012-0460-2","journal-title":"Pituitary"},{"key":"3227_CR37","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.2147\/ppa.S213472","volume":"13","author":"T Str\u00f6m","year":"2019","unstructured":"T. Str\u00f6m, G. Kozlovacki, P. Myrenfors, M. Almquist, Patient and nurse experience of using somatostatin analogues to treat gastroenteropancreatic neuroendocrine tumors: results of the somatostatin treatment experience trial (STREET). Patient Prefer Adherence 13, 1799\u20131807 (2019). https:\/\/doi.org\/10.2147\/ppa.S213472","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"3227_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12020-020-02529-5","volume":"71","author":"A Akirov","year":"2021","unstructured":"A. Akirov, H. Masri-Iraqi, A. Gorshtein, H. Duskin-Bitan, K. Kaminer, I. Shimon, Benefits of a nurse-led home injection service for acromegaly patients treated with somatuline autogel. Endocrine 71(2), 453\u2013458 (2021). https:\/\/doi.org\/10.1007\/s12020-020-02529-5","journal-title":"Endocrine"},{"issue":"12","key":"3227_CR39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/medicina57121287","volume":"57","author":"A Sowa-Staszczak","year":"2021","unstructured":"A. Sowa-Staszczak, M. Opali\u0144ska, A. Kurzy\u0144ska, K. Morawiec-S\u0142awek, A. Gilis-Januszewska, J. Palen-Tytko, H. Olearska, A. Hubalewska-Dydejczyk, Self-Administration of Long-Acting Somatostatin Analogues in NET Patients\u2014Does It Affect the Clinical Outcome? Medicina 57(12), 1287 (2021)","journal-title":"Medicina"},{"issue":"3","key":"3227_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/j.1365-2265.2007.03044.x","volume":"68","author":"JS Bevan","year":"2008","unstructured":"J.S. Bevan, J. Newell-Price, J.A. Wass, S.L. Atkin, P.M. Bouloux, J. Chapman, J.R. Davis, T.A. Howlett, H.S. Randeva, P.M. Stewart, A. Viswanath, Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin. Endocrinol. 68(3), 343\u2013349 (2008). https:\/\/doi.org\/10.1111\/j.1365-2265.2007.03044.x","journal-title":"Clin. Endocrinol."},{"key":"3227_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/ppa.S34337","volume":"6","author":"V Johanson","year":"2012","unstructured":"V. Johanson, B. Wilson, A. Abrahamsson, C. Jianu, J. Calissendorff, N. Wall, H. Gr\u00f8nb\u00e6k, J. Florholmen, A. Ohberg, D. Granberg, Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(\u00ae) given by either self\/partner or a health care professional. Patient Prefer Adherence 6, 703\u2013710 (2012). https:\/\/doi.org\/10.2147\/ppa.S34337","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"3227_CR42","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s11102-009-0207-x","volume":"13","author":"R Salvatori","year":"2010","unstructured":"R. Salvatori, L.B. Nachtigall, D.M. Cook, V. Bonert, M.E. Molitch, S. Blethen, S. Chang, Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-na\u00efve patients with acromegaly. Pituitary 13(2), 115\u2013122 (2010). https:\/\/doi.org\/10.1007\/s11102-009-0207-x","journal-title":"Pituitary"},{"key":"3227_CR43","doi-asserted-by":"publisher","first-page":"S522","DOI":"10.1016\/j.jval.2020.08.695","volume":"23","author":"B Harrow","year":"2020","unstructured":"B. Harrow, O. Cristeau, E. Clay, C. Francois, I. Frankcom, F. Marteau, PDG12 In the current COVID reality, can independent injection of somatostatin analogues lead to greater health savings? A budget impact analysis in the UK. Value Health 23, S522\u2013S523 (2020)","journal-title":"Value Health"},{"key":"3227_CR44","first-page":"135","volume":"33","author":"B Harrow","year":"2021","unstructured":"B. Harrow, O. Cristeau, E. Clay, C. Francois, I. Frankcom, L. Cortez, Independent administration of long-acting somatostatin analogues (SSAs) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET): Potential savings of increased uptake in the UK National Health Service (NHS). J. Neuroendocrinol. 33, 135 (2021)","journal-title":"J. Neuroendocrinol."},{"issue":"2","key":"3227_CR45","first-page":"201","volume":"33","author":"H Schulze-Koops","year":"2015","unstructured":"H. Schulze-Koops, R. Giacomelli, W. Samborski, S. Rednic, M. Herold, R. Yao, M. Govoni, N. Vastesaeger, H.H. Weng, Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. Clin. Exp. Rheumatol. 33(2), 201\u2013208 (2015)","journal-title":"Clin. Exp. Rheumatol."},{"issue":"5","key":"3227_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3109\/14397595.2015.1012786","volume":"25","author":"K Amano","year":"2015","unstructured":"K. Amano, T. Matsubara, T. Tanaka, H. Inoue, M. Iwahashi, T. Kanamono, T. Nakano, S. Uchimura, T. Izumihara, A. Yamazaki, C.S. Karyekar, T. Takeuchi, Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Mod. Rheumatol. 25(5), 665\u2013671 (2015). https:\/\/doi.org\/10.3109\/14397595.2015.1012786","journal-title":"Mod. Rheumatol."},{"issue":"4","key":"3227_CR47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.contraception.2016.05.006","volume":"94","author":"I Kaplan","year":"2016","unstructured":"I. Kaplan, D. Ross, F. Hilton, D. Morgenstern, K. Wolter, The role of training in effective simulated self-injection of subcutaneous depot medroxyprogesterone acetate: observations from a usability study. Contraception 94(4), 314\u2013320 (2016). https:\/\/doi.org\/10.1016\/j.contraception.2016.05.006","journal-title":"Contraception"},{"issue":"1","key":"3227_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0005-7916(02)00011-3","volume":"33","author":"DC Mohr","year":"2002","unstructured":"D.C. Mohr, D. Cox, L. Epstein, A. Boudewyn, Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. J. Behav. Ther. Exp. Psychiatry 33(1), 39\u201347 (2002). https:\/\/doi.org\/10.1016\/s0005-7916(02)00011-3","journal-title":"J. Behav. Ther. Exp. Psychiatry"},{"issue":"1","key":"3227_CR49","doi-asserted-by":"publisher","first-page":"e001828","DOI":"10.1136\/rmdopen-2021-001828","volume":"8","author":"C Beauvais","year":"2022","unstructured":"C. Beauvais, F. Fayet, A. Rousseau, C. Sordet, S. Pouplin, Y. Maugars, R.M. Poilverd, C. Savel, V. S\u00e9gard, B. Godon, Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial. RMD Open 8(1), e001828 (2022)","journal-title":"RMD Open"},{"issue":"Suppl 1","key":"3227_CR50","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1136\/annrheumdis-2020-eular.5505","volume":"79","author":"S Afilal","year":"2020","unstructured":"S. Afilal, H. Rkain, B. Berchane, J. Moulay Berkchi, S. Fellous, T. Fatima Zahrae, A. Ilham, N. Alami, T. Latifa, N. Hajjaj-Hassouni, F. Allali, Evolution of the perceptions of RA patients after education patient session teaching methotrexate self-injection a prospective pilot study. Ann. Rheum. Dis. 79(Suppl 1), 566 (2020). https:\/\/doi.org\/10.1136\/annrheumdis-2020-eular.5505","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"3227_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-1172-3-17","volume":"3","author":"P Chanson","year":"2008","unstructured":"P. Chanson, S. Salenave, Acromegaly. Orphanet J. Rare Dis. 3(1), 1\u201317 (2008)","journal-title":"Orphanet J. Rare Dis."},{"key":"3227_CR52","unstructured":"Ipsen Biopharmaceuticals: Ipsen announces U.S. FDA approval for newly designed pre-filled syringe for somatuline\u00ae depot (lanreotide). https:\/\/www.ipsen.com\/us\/blog\/press-releases\/ipsen-announces-u-s-fda-approval-for-newly-designed-pre-filled-syringe-for-somatuline-depot-lanreotide\/. Accessed 16 August 2022"},{"issue":"1","key":"3227_CR53","doi-asserted-by":"publisher","first-page":"269","DOI":"10.2147\/tcrm.s1458","volume":"4","author":"J Jin","year":"2008","unstructured":"J. Jin, G.E. Sklar, V. Min Sen Oh, S. Chuen Li, Factors affecting therapeutic compliance: A review from the patient\u2019s perspective. Ther. Clin. Risk Manag. 4(1), 269\u2013286 (2008). https:\/\/doi.org\/10.2147\/tcrm.s1458","journal-title":"Ther. Clin. Risk Manag."},{"issue":"6","key":"3227_CR54","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1590\/s0034-8910.2013047004834","volume":"47","author":"NU Tavares","year":"2013","unstructured":"N.U. Tavares, A.D. Bertoldi, E. Thum\u00e9, L.A. Facchini, G.V. Fran\u00e7a, S.S. Mengue, Factors associated with low adherence to medication in older adults. Rev. Saude Publica 47(6), 1092\u20131101 (2013). https:\/\/doi.org\/10.1590\/s0034-8910.2013047004834","journal-title":"Rev. Saude Publica"},{"key":"3227_CR55","first-page":"183","volume":"34","author":"D O'Toole","year":"2022","unstructured":"D. O'Toole, A. Prebtani, S. Webb, A. Houchard, D. Gueguen, S. Boiziau, P. Kunz, PRESTO 2: An international patient survey to evaluate impact of injection and delivery system on local pain when administering somatostatin analogue (SSA) therapy. J. Neuroendocrinol. 34, 183 (2022)","journal-title":"J. Neuroendocrinol."},{"key":"3227_CR56","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/prbm.S36238","volume":"9","author":"A Tomlin","year":"2016","unstructured":"A. Tomlin, A. Sinclair, The influence of cognition on self-management of type 2 diabetes in older people. Psychol. Res. Behav. Manag. 9, 7\u201320 (2016). https:\/\/doi.org\/10.2147\/prbm.S36238","journal-title":"Psychol. Res. Behav. Manag."},{"issue":"3","key":"3227_CR57","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40744-021-00325-9","volume":"8","author":"M Kishimoto","year":"2021","unstructured":"M. Kishimoto, F. Yamairi, N. Sato, J. Kobayashi, S. Yamauchi, T. Iwasaki, Patient preference for treatment mode of biologics in rheumatoid arthritis: A 2020 web-based survey in Japan. Rheumatol. Ther. 8(3), 1095\u20131111 (2021)","journal-title":"Rheumatol. Ther."},{"issue":"1","key":"3227_CR58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12875-020-01326-3","volume":"21","author":"K Danhieux","year":"2020","unstructured":"K. Danhieux, V. Buffel, A. Pairon, A. Benkheil, R. Remmen, E. Wouters, J. van Olmen, The impact of COVID-19 on chronic care according to providers: a qualitative study among primary care practices in Belgium. BMC Fam. Pr. 21(1), 255 (2020). https:\/\/doi.org\/10.1186\/s12875-020-01326-3","journal-title":"BMC Fam. Pr."},{"key":"3227_CR59","unstructured":"The Joanna Briggs Institute: Critical appraisal tools for use in JBI systematic seviews: checklist for text and opinion. https:\/\/jbi.global\/sites\/default\/files\/2019-05\/JBI_Critical_Appraisal-Checklist_for_Text_and_Opinion2017_0.pdf (2017). Accessed 16 August 2022"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03227-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03227-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:48:57Z","timestamp":1744206537000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03227-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["3227"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03227-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"assertion":[{"value":"13 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"C.L.B.: Speaker\u2019s bureau from Novartis; principal investigator for Novartis and Crinetics clinical trials; M.K.: Speaker\u2019s bureau from Ipsen, NovoNordisk, Pfizer; grant support from Crinetics and ONO; A.A.: Employee of Costello Medical; A.M.G.: Member of the Spanish Association of Acromegaly; A.H.: Employee of Ipsen; holds stock options in Ipsen; A.R.O.J.: Employee of Ipsen; holds stock options in Ipsen; W.W.d.H.: Speaker\u2019s bureau from Ipsen and Novartis; research support from Novartis; advisory board member for Camurus and Crinetics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}